Condition: Perianal Fistula Due to Crohn's Disease · Sponsor: Direct Biologics, LLC
This is a double-blind, randomized, placebo-controlled, sequential cohort, ascending dose clinical trial to evaluate the safety and determine the efficacy of ascending doses of DB-3Q for the treatment of Perianal Fistulizing Crohn's Disease.
This description comes directly from the study's public registry record.
Executive Vice President, Clinical Affairs, MS · 1-800-791-1021 · clinicalaffairs@directbiologics.com
Always discuss trial participation with your own doctor first.
| Direct Biologics Investigational Site | Aurora, Colorado, United States | Recruiting |
| Direct Biologics Investigational Site | St Louis, Missouri, United States | Recruiting |
| Columbia University Irving Medical Center/NYPH | New York, New York, United States | Recruiting |
| Direct Biologics Investigational Site | Philadelphia, Pennsylvania, United States | Recruiting |
| Direct Biologics Investigational Site | Nashville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06918808